XORTX Therapeutics Inc (XRTX)
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
Nutrien Cautions Investors Regarding Ocehan LLC’s Below Market “Mini-Tender” Offer
COMP Investors Have Opportunity to Join Compass, Inc. Fraud Investigation with the Schall Law Firm
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
Lotus Tech Announces Operational and Earnings Reporting Updates
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
Summit Plc - Current report filing
TAL Education Group Files Its Annual Report on Form 20-F
Bluerock Homes Trust (BHM) Announces Second Quarter Dividends on Common Stock
ETC Announces Fiscal 2026 Full Year and Fourth Quarter Results